Middle East & Africa Enzyme Replacement Therapy Market is expected to reach US$ 386.56 million by 2028

At 4.5% CAGR, the Middle East & Africa Enzyme Replacement Therapy Market is speculated to be worth US$ 386.56 million by 2028, says Business Market Insights         

According to the Insight Partners’ research, the Middle East & Africa enzyme replacement therapy market was valued at US$ 297.32 million in 2022 and is expected to reach US$ 386.56 million by 2028, registering an annual growth rate of 4.5% from 2022 to 2028.Rapid regulatory approval with other benefits for drug with orphan drug designation and rising prevalence of lysosomal storage diseases (LSDs) are the critical factors attributed to the market expansion.                

An orphan disease is defined as a condition that affects fewer than 200,000 people nationwide. Fabry's disease, Pompe disease, and Hunter syndrome are a few examples of orphan diseases. Drugs used to treat orphan diseases are known as orphan drugs, and these drugs have a special regulatory designation for rapid approval. Orphan drug designation is a status given to certain drugs called orphan drugs, which show promise in the treatment and prevention of orphan diseases. Thus, the rapid regulatory approval with other marketing benefits for the drug with orphan drug designation is driving the market growth.  

On the contrary, cutthroat competition among market players hurdles the growth of Middle East & Africa enzyme replacement therapy market.

• Based on enzyme type, the Middle East & Africa enzyme replacement therapy market is segmented into alglucosidase alfa, agalsidase beta, imiglucerase, idursulfase, galsulfase, velaglucerase alfa, and other enzymes. The other enzymes segment held 41.8% market share in 2022, amassing US$ 124.21 million. It is projected to garner US$ 166.89 million by 2028 to expand at 5.0% CAGR during 2022–2028.
• Based on therapeutic conditions, the Middle East & Africa enzyme replacement therapy market is segmented into gaucher's disease, fabry's disease, MPS, pompe's disease, SCID, and other therapeutic conditions. The gaucher's disease segment held 26.7% market share in 2022, amassing US$ 79.44 million. It is projected to garner US$ 108.48 million by 2028 to expand at 5.3% CAGR during 2022–2028.
• Based on route of administration, the Middle East & Africa enzyme replacement therapy market is bifurcated into parenteral and oral. The parenteral segment held 78.8% market share in 2022, amassing US$ 234.436 million. It is projected to garner US$ 307.730 million by 2028 to expand at 4.6% CAGR during 2022–2028.
• Based on end user, the Middle East & Africa enzyme replacement therapy market is segmented into hospitals, infusion centers, and others. The hospitals segment held 57.2% market share in 2022, amassing US$ 170.015 million. It is projected to garner US$ 219.517 million by 2028 to expand at 4.4% CAGR during 2022–2028.
• Based on country, the Middle East & Africa enzyme replacement therapy market has been categorized into Saudi Arabia, South Africa, UAE, and rest of Middle East & Africa.  Our regional analysis states that Saudi Arabia captured 35.91% market share in 2022. It was assessed at US$ 106.76 million in 2022 and is likely to hit US$ 143.64 million by 2028, exhibiting a CAGR of 5.1% during the forecast period.  

Key players dominating the Middle East & Africa enzyme replacement therapy market are Sanofi; BioMarine Pharmaceutical Inc; Takeda Pharmaceutical Company Limited; AbbVie Inc; Janssen Pharmaceutical (Johnson & Johnson Services, Inc.); Alexion Pharmaceutical, Inc. (AstaZeneca); Amicus Therapeutics; Recordati S.p.A; Recordati S.p.A; CHIESI farmaceutici S.p.A; and Pfizer Inc, among others.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com